Sugi Predict

Sugi Predict / Compounds / SCHEMBL389893

SCHEMBL389893

SCHEMBL389893

COC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)ccc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.44
▸ HIF1A Q16665 3/20 0.42
▸ DGAT1 O75907 1/20 0.40
▸ AAK1 Q2M2I8 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ P4HB P07237 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863066 0.89 CSF1R (0.44) CSF1RHIF1ADGAT1AAK1KDM4E
SCHEMBL31061615 0.89 CSF1R (0.44) CSF1RHIF1ADGAT1AAK1KDM4E
SCHEMBL25225416 0.87 CSF1R (0.44) CSF1RHIF1AKDM4EP4HBCA1
SCHEMBL25035049 0.87 HIF1A (0.43) CSF1RHIF1ADGAT1KDM4EP4HB
SCHEMBL25235246 0.87 AAK1 (0.46) CSF1RHIF1ADGAT1AAK1KDM4E
SCHEMBL3517005 0.87 UCHL1 (0.43) CSF1RHIF1AGAALMNAKMT2A
SCHEMBL17042803 0.86 CSF1R (0.44) CSF1RHIF1ADGAT1AAK1P4HB
SCHEMBL20190363 0.85 F2 (0.40) CSF1RHIF1ADGAT1AAK1P4HB
SCHEMBL15386719 0.85 HIF1A (0.42) CSF1RHIF1ADGAT1AAK1P4HB
SCHEMBL2281668 0.84 ALDH1A1 (0.51) HIF1ADGAT1KDM4EGAACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268903-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-08-28 — — US disclosed
US-20240336618-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-10-10 — — US disclosed
EP-4423058-A1 RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-09-04 — — EP disclosed
CN-117069728-A PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2023-11-17 — — CN disclosed
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 — — US disclosed
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 — — US disclosed
CN-111868063-B PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2023-08-01 — — CN disclosed
WO-2023114823-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-22 — — WO disclosed
WO-2023114823-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-22 — — WO disclosed
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-05-16 — — US disclosed
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2008-08-14 — — US disclosed
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2008-08-14 — — US disclosed
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2008-08-14 — — US disclosed
US-20080081809-A1 Novel Compounds KUDOS PHARMACEUTICALS LIMITED (GB) 2008-04-03 — — US disclosed
US-20080081809-A1 Novel Compounds KUDOS PHARMACEUTICALS LIMITED (GB) 2008-04-03 — — US disclosed
US-20080081809-A1 Novel Compounds KUDOS PHARMACEUTICALS LIMITED (GB) 2008-04-03 — — US disclosed
WO-2008023161-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2008-02-28 — — WO disclosed
WO-2008023161-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2008-02-28 — — WO disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 — — US disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250268903-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 CSF1R 228/4885HIF1A 744/4885DGAT1 1039/4885
US-20230348363-A1 COMPOUNDS AND THEIR USE RXFP1, RXFP3, RXFP2 CSF1R 501/4885HIF1A 362/4885DGAT1 2748/4885
US-11649238-B2 Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors PI4K2A, PI4K2B, PI4KA CSF1R 3127/4885HIF1A 3002/4885DGAT1 4312/4885
US-20240336618-A1 PI4KIIIBETA INHIBITORS PI4KB, PI4K2B, PI4K2A CSF1R 2396/4885HIF1A 2573/4885DGAT1 3433/4885
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR CSF1R 491/4885HIF1A 381/4885DGAT1 858/4885
US-20080081809-A1 Novel Compounds SLC10A1, ABCB11, PKD1 CSF1R 1240/4885HIF1A 848/4885DGAT1 1794/4885
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors RPS6KB1, RPS6KA1, RPS3A CSF1R 2551/4885HIF1A 1888/4885DGAT1 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.